$INBP
INTEGRATED BIOPHARMA INC

2015 Form 10-K Financial Statement

#000101650415000010 Filed on September 04, 2015

View on sec.gov

Income Statement

Concept 2015 2014 Q2 2014
Revenue $37.49M $8.180M $33.68M
YoY Change 11.3% -14.79% 0.19%
Cost Of Revenue $33.10M $7.090M $28.80M
YoY Change 14.91% -11.82% 2.42%
Gross Profit $4.393M $1.090M $4.883M
YoY Change -10.03% -30.13% -11.22%
Gross Profit Margin 11.72% 13.33% 14.5%
Selling, General & Admin $3.460M $820.0K $3.531M
YoY Change -2.01% -15.46% -16.92%
% of Gross Profit 78.76% 75.23% 72.31%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $405.0K $90.00K $253.0K
YoY Change 60.08% -18.18% -41.16%
% of Gross Profit 9.22% 8.26% 5.18%
Operating Expenses $3.460M $830.0K $3.531M
YoY Change -2.01% -17.0% -19.57%
Operating Profit $933.0K $260.0K $1.352M
YoY Change -30.99% -53.57% 21.8%
Interest Expense $979.0K -$270.0K $964.0K
YoY Change 1.56% -217.39% -186.85%
% of Operating Profit 104.93% -103.85% 71.3%
Other Income/Expense, Net -$64.00K $0.00 -$1.132M
YoY Change -94.35% -552.8%
Pretax Income $869.0K -$160.0K $220.0K
YoY Change 295.0% -120.51% 100.0%
Income Tax $134.0K -$40.00K $89.00K
% Of Pretax Income 15.42% 40.45%
Net Earnings $735.0K -$110.0K $131.0K
YoY Change 461.07% -114.1% 45.56%
Net Earnings / Revenue 1.96% -1.34% 0.39%
Basic Earnings Per Share $0.03 $0.01
Diluted Earnings Per Share $0.02 -$5.216K $0.01
COMMON SHARES
Basic Shares Outstanding 21.11M 21.08M
Diluted Shares Outstanding 29.39M 21.19M

Balance Sheet

Concept 2015 2014 Q2 2014
SHORT-TERM ASSETS
Cash & Short-Term Investments $572.0K $980.0K $980.0K
YoY Change -41.63% 32.43% 32.43%
Cash & Equivalents $451.0K
Short-Term Investments $501.0K $530.0K $530.0K
Other Short-Term Assets $334.0K $306.0K $310.0K
YoY Change 7.74% -10.0% -8.82%
Inventory $5.778M $5.698M $5.700M
Prepaid Expenses
Receivables $2.638M $2.179M $2.180M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $9.322M $9.166M $9.170M
YoY Change 1.66% -7.69% -7.65%
LONG-TERM ASSETS
Property, Plant & Equipment $1.373M $1.373M $1.240M
YoY Change 10.73% 10.73% 0.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $185.0K $300.0K $300.0K
YoY Change -38.33% -30.23% -30.23%
Total Long-Term Assets $2.301M $2.417M $2.410M
YoY Change -4.52% -9.81% -10.07%
TOTAL ASSETS
Total Short-Term Assets $9.322M $9.166M $9.170M
Total Long-Term Assets $2.301M $2.417M $2.410M
Total Assets $11.62M $11.58M $11.58M
YoY Change 0.37% -8.14% -8.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.148M $5.635M $5.640M
YoY Change -8.72% -4.17% -4.08%
Accrued Expenses $1.536M $1.310M $1.310M
YoY Change 17.25% 16.96% 16.96%
Deferred Revenue
YoY Change
Short-Term Debt $4.462M $4.120M $4.120M
YoY Change 8.3% -9.25% -9.25%
Long-Term Debt Due $719.0K $588.0K $590.0K
YoY Change 21.86% -32.41% -32.18%
Total Short-Term Liabilities $11.87M $11.65M $11.65M
YoY Change 1.85% -6.18% -6.2%
LONG-TERM LIABILITIES
Long-Term Debt $9.062M $4.359M $9.370M
YoY Change -3.29% -55.47% -4.29%
Other Long-Term Liabilities $12.00K $720.0K $720.0K
YoY Change -98.33% 2.86% 2.86%
Total Long-Term Liabilities $9.074M $4.359M $10.09M
YoY Change -10.07% -58.45% -3.81%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.87M $11.65M $11.65M
Total Long-Term Liabilities $9.074M $4.359M $10.09M
Total Liabilities $20.94M $21.74M $21.74M
YoY Change -3.68% -5.07% -5.07%
SHAREHOLDERS EQUITY
Retained Earnings -$54.67M
YoY Change
Common Stock $42.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $99.00K
YoY Change
Treasury Stock Shares $34.90K
Shareholders Equity -$9.316M -$10.16M -$10.16M
YoY Change
Total Liabilities & Shareholders Equity $11.62M $11.58M $11.58M
YoY Change 0.37% -8.14% -8.17%

Cashflow Statement

Concept 2015 2014 Q2 2014
OPERATING ACTIVITIES
Net Income $735.0K -$110.0K $131.0K
YoY Change 461.07% -114.1% 45.56%
Depreciation, Depletion And Amortization $405.0K $90.00K $253.0K
YoY Change 60.08% -18.18% -41.16%
Cash From Operating Activities -$113.0K -$220.0K $1.877M
YoY Change -106.02% -62.07% -230.35%
INVESTING ACTIVITIES
Capital Expenditures $235.0K -$60.00K $182.0K
YoY Change 29.12% 500.0% -706.67%
Acquisitions
YoY Change
Other Investing Activities $79.00K $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$156.0K -$60.00K -$182.0K
YoY Change -14.29% 500.0% 1720.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -111.0K 550.0K -1.299M
YoY Change -91.45% 52.78% -195.51%
NET CHANGE
Cash From Operating Activities -113.0K -220.0K 1.877M
Cash From Investing Activities -156.0K -60.00K -182.0K
Cash From Financing Activities -111.0K 550.0K -1.299M
Net Change In Cash -380.0K 270.0K 396.0K
YoY Change -195.96% -217.39% -540.0%
FREE CASH FLOW
Cash From Operating Activities -$113.0K -$220.0K $1.877M
Capital Expenditures $235.0K -$60.00K $182.0K
Free Cash Flow -$348.0K -$160.0K $1.695M
YoY Change -120.53% -71.93% -220.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015 dei Document Type
DocumentType
10-K
CY2015 dei Document Period End Date
DocumentPeriodEndDate
2015-06-30
CY2015 dei Entity Registrant Name
EntityRegistrantName
INTEGRATED BIOPHARMA INC
CY2015 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2015 dei Entity Central Index Key
EntityCentralIndexKey
0001016504
CY2015Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21105174
CY2015 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2015 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2015 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2015Q2 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
CY2015 dei Amendment Flag
AmendmentFlag
false
CY2015 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2015 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q4 dei Entity Public Float
EntityPublicFloat
826567
CY2015 inbp Accretion On Convertible Debt Net Of Tax
AccretionOnConvertibleDebtNetOfTax
110000
CY2015 inbp Accretion On Embedded Derivative Feature
AccretionOnEmbeddedDerivativeFeature
110000
CY2014 inbp Accretion On Embedded Derivative Feature
AccretionOnEmbeddedDerivativeFeature
108000
CY2015 inbp Cash Discount On Property
CashDiscountOnProperty
2000
CY2014 inbp Cash Discount On Property
CashDiscountOnProperty
4000
CY2015Q2 inbp Discount For Embeddedderivative
DiscountForEmbeddedderivative
230000
CY2014Q2 inbp Discount For Embeddedderivative
DiscountForEmbeddedderivative
341000
CY2014 inbp Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
1500000
CY2015 inbp Effective Income Tax Rate Reconciliation Statutory Minimum Taxes Percent
EffectiveIncomeTaxRateReconciliationStatutoryMinimumTaxesPercent
0.09
CY2014 inbp Effective Income Tax Rate Reconciliation Statutory Minimum Taxes Percent
EffectiveIncomeTaxRateReconciliationStatutoryMinimumTaxesPercent
0.4
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
100000
CY2015Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
71000
CY2014Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
91000
CY2014 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
137000
CY2015 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2013 inbp Minimumebitda
Minimumebitda
1500000
CY2015Q2 inbp Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Originally Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesOriginallyAuthorized
7000000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5148000
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5635000
CY2015Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
290000
CY2014Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
184000
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2638000
CY2014Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2179000
CY2015 us-gaap Accretion Expense
AccretionExpense
239000
CY2014 us-gaap Accretion Expense
AccretionExpense
237000
CY2015Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1536000
CY2014Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1309000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6414000
CY2014Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6305000
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44676000
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
44572000
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
104000
CY2015 us-gaap Advertising Cost Policy Expensed Advertising Cost
AdvertisingCostPolicyExpensedAdvertisingCost
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Trade Marketing and Merchandising.</div></div> In order to support the Company&#x2019;s proprietary nutraceutical product lines, various promotional activities are conducted through the retail trade, distributors or directly with consumers, including in-store display and product placement programs, feature price discounts, coupons, and other similar activities. The Company regularly reviews and revises, when it deems necessary, estimates of costs to the Company for these promotional programs based on estimates of what will be redeemed by the retail trade, distributors, or consumers. These estimates are made using various techniques, including historical data on performance of similar promotional programs. Differences between estimated expense and actual performance are generally not material and are recognized as a change in management&#x2019;s estimate in a subsequent period. </div></div></div></div></div></div></div>
CY2015 us-gaap Advertising Expense
AdvertisingExpense
38000
CY2014 us-gaap Advertising Expense
AdvertisingExpense
4000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2139550
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9467539
CY2015Q2 us-gaap Assets
Assets
11623000
CY2014Q2 us-gaap Assets
Assets
11583000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
9322000
CY2014Q2 us-gaap Assets Current
AssetsCurrent
9166000
CY2015Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
125000
CY2014Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
83000
CY2015 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
185000
CY2014 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
72000
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
451000
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-380000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
396000
CY2015Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2015Q2 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6000
CY2015Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21140074
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21140074
CY2015Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21105174
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21105174
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
42000
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
42000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
33095000
CY2014 us-gaap Cost Of Goods Sold
CostOfGoodsSold
28800000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
134000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
89000
CY2015 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
44000
CY2015Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.0466
CY2014Q2 us-gaap Debt Weighted Average Interest Rate
DebtWeightedAverageInterestRate
0.0468
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-231000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-422000
CY2015Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
31000
CY2014Q2 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
CY2015Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
180000
CY2014Q2 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
261000
CY2015Q2 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
695000
CY2014Q2 us-gaap Deferred Tax Assets Investments
DeferredTaxAssetsInvestments
737000
CY2015Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2014Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2014Q2 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
CY2015Q2 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
CY2014Q2 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
CY2015Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14307000
CY2014Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
14661000
CY2015Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
-12000
CY2014Q2 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
540000
CY2015Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15137000
CY2014Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16062000
CY2015Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
64000
CY2014Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
137000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
64000
CY2014 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
71000
CY2015Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
185000
CY2014Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
298000
CY2015 us-gaap Depreciation
Depreciation
268000
CY2014 us-gaap Depreciation
Depreciation
253000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
405000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
390000
CY2015 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
705000
CY2014 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-21000
CY2015Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
12000
CY2014Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
717000
CY2015 us-gaap Dilutive Securities
DilutiveSecurities
-705000
CY2014 us-gaap Dilutive Securities
DilutiveSecurities
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2014 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.01
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2014 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.01
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.15
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.4
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.39
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.45
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.05
CY2014 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.05
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2015Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
75000
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1676000
CY2014Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1539000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
251000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
104000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
97000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
97000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
97000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
97000
CY2015Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2419000
CY2014Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2419000
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
743000
CY2014Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
880000
CY2015 us-gaap Gain Loss On Investments
GainLossOnInvestments
CY2014 us-gaap Gain Loss On Investments
GainLossOnInvestments
-152000
CY2015 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
48000
CY2014 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
3000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
4000
CY2015 us-gaap Gross Profit
GrossProfit
4393000
CY2014 us-gaap Gross Profit
GrossProfit
4883000
CY2013Q4 us-gaap Guarantee Obligations Maximum Exposure
GuaranteeObligationsMaximumExposure
1000000
CY2015 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2014 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2014 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
869000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
220000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
134000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
89000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
231000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
422000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
158000
CY2014 us-gaap Income Taxes Paid
IncomeTaxesPaid
7000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-488000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-247000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
440000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-248000
CY2015 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-705000
CY2014 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
21000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
79000
CY2014 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-733000
CY2015 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
229000
CY2014 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
187000
CY2015 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
42000
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-36000
CY2015 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
8230769
CY2015 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
49944
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
111863
CY2015 us-gaap Interest Expense
InterestExpense
979000
CY2014 us-gaap Interest Expense
InterestExpense
964000
CY2015 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
5000
CY2014 us-gaap Interest Expense Lessee Assets Under Capital Lease
InterestExpenseLesseeAssetsUnderCapitalLease
5000
CY2015 us-gaap Interest Expense Other
InterestExpenseOther
33000
CY2014 us-gaap Interest Expense Other
InterestExpenseOther
22000
CY2015 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
129000
CY2014 us-gaap Interest Expense Subordinated Notes And Debentures
InterestExpenseSubordinatedNotesAndDebentures
129000
CY2015 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
326000
CY2012Q2 us-gaap Interest Paid
InterestPaid
333000
CY2015 us-gaap Interest Paid
InterestPaid
714000
CY2014 us-gaap Interest Paid
InterestPaid
716000
CY2015Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
114000
CY2014Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
88000
CY2015Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1346000
CY2014Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1631000
CY2015Q2 us-gaap Inventory Net
InventoryNet
5778000
CY2014Q2 us-gaap Inventory Net
InventoryNet
5698000
CY2015Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2371000
CY2014Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2851000
CY2015Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2061000
CY2014Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1216000
CY2014 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1000000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1000000
CY2015Q2 us-gaap Liabilities
Liabilities
20939000
CY2014Q2 us-gaap Liabilities
Liabilities
21738000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11623000
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11583000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11865000
CY2014Q2 us-gaap Liabilities Current
LiabilitiesCurrent
11653000
CY2015Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2014Q2 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2015Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4462000
CY2014Q2 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
4121000
CY2015Q2 us-gaap Long Term Debt
LongTermDebt
9123000
CY2014Q2 us-gaap Long Term Debt
LongTermDebt
9068000
CY2015Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
719000
CY2014Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
588000
CY2015Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3942000
CY2014Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4359000
CY2015Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
4462000
CY2014Q2 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
4121000
CY2012Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
3727000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-111000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1299000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-182000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-113000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1877000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
735000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
131000
CY2015 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
466000
CY2014 us-gaap Net Income Loss Attributable To Parent Diluted
NetIncomeLossAttributableToParentDiluted
131000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
618000
CY2015 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-64000
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1132000
CY2015Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
5120000
CY2014Q2 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
5009000
CY2015 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
933000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
1352000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
5991000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
564000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
565000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
577000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
587000
CY2015Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
3080000
CY2015Q2 us-gaap Other Assets Current
OtherAssetsCurrent
334000
CY2014Q2 us-gaap Other Assets Current
OtherAssetsCurrent
306000
CY2012Q2 us-gaap Other Expenses
OtherExpenses
217000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
210000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5000
CY2015 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
422000
CY2014 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
258000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
235000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
182000
CY2015 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Reclassifications.</div></div> Certain reclassifications have been made to the amounts reported in these notes to consolidated financial statements for the prior year to conform to the current year presentation. </div></div></div></div></div></div></div>
CY2015 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
36993000
CY2014 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
32341000
CY2015 us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
79000
CY2014 us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
CY2015 us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
307000
CY2014 us-gaap Proceeds From Secured Lines Of Credit
ProceedsFromSecuredLinesOfCredit
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2015 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
132000
CY2014 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
72000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7787000
CY2014Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7544000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1373000
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1239000
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
6.36
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-20000
CY2014 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-7000
CY2015 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
36652000
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
32763000
CY2015 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
143000
CY2014 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
47000
CY2015 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
616000
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
834000
CY2015Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
501000
CY2014Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
532000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-53935000
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54670000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
37488000
CY2014 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
33683000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
37488000
CY2014 us-gaap Sales Revenue Net
SalesRevenueNet
33683000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3460000
CY2014 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3531000
CY2012Q2 us-gaap Senior Notes
SeniorNotes
11727000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
6000000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
13000000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1724520
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2164550
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.07
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.70
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
976318
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
881570
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
73000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
18000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2248000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2248000
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2798838
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1724520
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3072950
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.72
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.52
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.14
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
9.04
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2015 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
104000
CY2014 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.31
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.11
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.09
CY2015 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.09
CY2015 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.48
CY2015Q2 us-gaap Share Price
SharePrice
0.09
CY2014Q2 us-gaap Share Price
SharePrice
0.25
CY2012Q2 us-gaap Share Price
SharePrice
0.09
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
68000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y292D
CY2015 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
247000
CY2014 us-gaap Shipping Handling And Transportation Costs
ShippingHandlingAndTransportationCosts
256000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
-9316000
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
-10155000
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
-10290000
CY2015Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
34900
CY2014Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
34900
CY2015Q2 us-gaap Treasury Stock Value
TreasuryStockValue
99000
CY2014Q2 us-gaap Treasury Stock Value
TreasuryStockValue
99000
CY2015 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Use of Estimates.</div></div> The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The most significant estimates include: </div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 18pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="WIDTH: 41pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">?</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">sales returns and allowances;</div></div></td> </tr> </table><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 18pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="WIDTH: 41pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">?</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">trade marketing and merchandising;</div></div></td> </tr> </table><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 18pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="WIDTH: 41pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">?</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">allowance for doubtful accounts;</div></div></td> </tr> </table><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 18pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="WIDTH: 41pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">?</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">inventory valuation;</div></div></td> </tr> </table><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 18pt">&nbsp;</td> <td style="WIDTH: 41pt; VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">?</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=" MARGIN-BOTTOM: 0pt; TEXT-ALIGN: justify; MARGIN-TOP: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">valuation and recoverability of long-lived and intangible assets; </div></div></td> </tr> </table><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 18pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="WIDTH: 41pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">?</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">income taxes and valuation allowance on deferred income taxes, and;</div></div></td> </tr> </table><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="WIDTH: 18pt"> <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div></td> <td style="WIDTH: 41pt; VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">?</div></div></td> <td style="VERTICAL-ALIGN: top"> <div style=""><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">accruals for, and the probability of, the outcome of any current litigation.</div></div></td> </tr> </table><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt 0pt 0pt 18pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. </div></div></div></div></div></div></div>
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29385887
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21193818
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21105174
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21081955

Files In Submission

Name View Source Status
0001016504-15-000010-index-headers.html Edgar Link pending
0001016504-15-000010-index.html Edgar Link pending
0001016504-15-000010.txt Edgar Link pending
0001016504-15-000010-xbrl.zip Edgar Link pending
exhibit21.htm Edgar Link pending
exhibit23_1.htm Edgar Link pending
exhibit31_1.htm Edgar Link pending
exhibit31_2.htm Edgar Link pending
exhibit32_1.htm Edgar Link pending
exhibit32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
inb001.jpg Edgar Link pending
inb002.jpg Edgar Link pending
inb003.jpg Edgar Link pending
inb004.jpg Edgar Link pending
inb005.jpg Edgar Link pending
inb006.jpg Edgar Link pending
inb007.jpg Edgar Link pending
inb008a.jpg Edgar Link pending
inb008b.jpg Edgar Link pending
inb009a.jpg Edgar Link pending
inb009b.jpg Edgar Link pending
inb010.jpg Edgar Link pending
inb011a.jpg Edgar Link pending
inb011b.jpg Edgar Link pending
inb012.jpg Edgar Link pending
inb013.jpg Edgar Link pending
inb014.jpg Edgar Link pending
inb015.jpg Edgar Link pending
inb016.jpg Edgar Link pending
inb017.jpg Edgar Link pending
inb018.jpg Edgar Link pending
inb019.jpg Edgar Link pending
inb020.jpg Edgar Link pending
inb021.jpg Edgar Link pending
inb022.jpg Edgar Link pending
inb023.jpg Edgar Link pending
inb024.jpg Edgar Link pending
inb025.jpg Edgar Link pending
inb026.jpg Edgar Link pending
inb027.jpg Edgar Link pending
inb10k_20150630.htm Edgar Link pending
inbp-20150630.xml Edgar Link completed
inbp-20150630.xsd Edgar Link pending
inbp-20150630_cal.xml Edgar Link unprocessable
inbp-20150630_def.xml Edgar Link unprocessable
inbp-20150630_lab.xml Edgar Link unprocessable
inbp-20150630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending